Cargando…
In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours
Nanostructure lipid carriers (NLCs) were developed for the delivery of curmumin (CRN), a potent anticancer agent with low bioavailability, for the treatment of prostate cancer. NLCs prepared using high pressure homogenization (HPH) with around 150 nm particle size, − 40 V ζ-potential and excellent l...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315352/ https://www.ncbi.nlm.nih.gov/pubmed/34845679 http://dx.doi.org/10.1007/s13346-021-01095-1 |
_version_ | 1785067491576250368 |
---|---|
author | Akanda, Mushfiq Getti, Giulia Douroumis, Dennis |
author_facet | Akanda, Mushfiq Getti, Giulia Douroumis, Dennis |
author_sort | Akanda, Mushfiq |
collection | PubMed |
description | Nanostructure lipid carriers (NLCs) were developed for the delivery of curmumin (CRN), a potent anticancer agent with low bioavailability, for the treatment of prostate cancer. NLCs prepared using high pressure homogenization (HPH) with around 150 nm particle size, − 40 V ζ-potential and excellent long-term stability. Cellular uptake of CRN-SLN showed nanoparticle localization in the cytoplasm around the nucleus. CRN-NLCs were assessed using flow cytometry and found to cause early and late apoptotic events at 100 μg/ml CRN concentrations. CRN-NLC nanoparticles were administrated to nude mice with LNCaP prostate cancer xenografts and demonstrated substantial tumour volume suppression (40%) with no weight loss compared to pure CRN (ethanolic solution). Overall, NLCs were proved a suitable carrier for passive drug delivery and cancer treatment. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-021-01095-1. |
format | Online Article Text |
id | pubmed-10315352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-103153522023-07-04 In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours Akanda, Mushfiq Getti, Giulia Douroumis, Dennis Drug Deliv Transl Res Original Article Nanostructure lipid carriers (NLCs) were developed for the delivery of curmumin (CRN), a potent anticancer agent with low bioavailability, for the treatment of prostate cancer. NLCs prepared using high pressure homogenization (HPH) with around 150 nm particle size, − 40 V ζ-potential and excellent long-term stability. Cellular uptake of CRN-SLN showed nanoparticle localization in the cytoplasm around the nucleus. CRN-NLCs were assessed using flow cytometry and found to cause early and late apoptotic events at 100 μg/ml CRN concentrations. CRN-NLC nanoparticles were administrated to nude mice with LNCaP prostate cancer xenografts and demonstrated substantial tumour volume suppression (40%) with no weight loss compared to pure CRN (ethanolic solution). Overall, NLCs were proved a suitable carrier for passive drug delivery and cancer treatment. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13346-021-01095-1. Springer US 2021-11-29 2023 /pmc/articles/PMC10315352/ /pubmed/34845679 http://dx.doi.org/10.1007/s13346-021-01095-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Akanda, Mushfiq Getti, Giulia Douroumis, Dennis In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title | In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title_full | In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title_fullStr | In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title_full_unstemmed | In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title_short | In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours |
title_sort | in vivo evaluation of nanostructured lipid carrier systems (nlcs) in mice bearing prostate cancer tumours |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315352/ https://www.ncbi.nlm.nih.gov/pubmed/34845679 http://dx.doi.org/10.1007/s13346-021-01095-1 |
work_keys_str_mv | AT akandamushfiq invivoevaluationofnanostructuredlipidcarriersystemsnlcsinmicebearingprostatecancertumours AT gettigiulia invivoevaluationofnanostructuredlipidcarriersystemsnlcsinmicebearingprostatecancertumours AT douroumisdennis invivoevaluationofnanostructuredlipidcarriersystemsnlcsinmicebearingprostatecancertumours |